Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Cancer Research

• Publication date

  2004-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-04-1187PMID 15534081
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.

  2004cited by this paper
• Targeting the HER-kinase axis in cancer.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer.

  2003cited by this paper
• Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition.

  2003cited by this paper
• Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

  2003cited by this paper
• Signal events: Cell signal transduction and its inhibition in cancer.

  2003cited by this paper
• Epidermal growth factor receptor dependence in human tumors: more than just expression?

  2002cited by this paper
• Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer.

  2002cited by this paper
• Drug‐induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy

  2002cited by this paper
• The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.

  2001cited by this paper
• Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.

  2001cited by this paper
• The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms

  2000cited by this paper
• The ErbB signaling network: receptor heterodimerization in development and cancer

  2000cited by this paper
• Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer.

  2000cited by this paper
• Gains of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis.

  1999cited by this paper
• Epidermal growth factor receptor expression in primary laryngeal cancer: An independent prognostic factor of neck node relapse

  1999cited by this paper
• Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

  1998cited by this paper
• Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha.

  1998cited by this paper
• Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas.

  1997cited by this paper
• A potential autocrine loop between heregulin-alpha and erbB-3 receptor in human prostatic adenocarcinoma.

  1997cited by this paper
• Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials.

  1997cited by this paper
• Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor.

  1997cited by this paper
• Unliganded Epidermal Growth Factor Receptor Dimerization Induced by Direct Interaction of Quinazolines with the ATP Binding Site*

  1997cited by this paper
• Involvement of Heregulin-β2 in the Acquisition of the Hormone-independent Phenotype of Breast Cancer Cells

  1996cited by this paper
• Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells.

  1996cited by this paper
• Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis.

  1996cited by this paper
• Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.

  1995cited by this paper
• Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer.

  1995cited by this paper
• The biology of erbB-2/neu/HER-2 and its role in cancer.

  1994cited by this paper
• The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients.

  1992cited by this paper
• Amplification of Epidermal Growth Factor Receptor Gene in Gliomas: Histopathology and Prognosis

  1992cited by this paper
• Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer.

  1991cited by this paper
• Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer.

  1985cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Optimizing intermittent dosing of oral small molecule inhibitors.

  2025cites this paper
• Exploratory Food Effect Assessment in Patients in Early Clinical Development of Oncology Drugs

  2023cites this paper
• Visible-light promoted catalyst-free (VLCF) multi-component synthesis of spiro indolo-quinazolinone-pyrrolo[3,4-a]pyrrolizine hybrids: evaluation of in vitro anticancer activity, molecular docking, MD simulation and DFT studies

  2023cites this paper
• Sensitivity of EGFR/HER-2 Positive Cells Isolated from Ascitic Fluid of Advanced Ovarian Cancer Patients to EGFR/HER-2 Inhibitors

  2020cites this paper
• Clinical Trial Outcomes: What Matters to Patients.

  2019cites this paper
• Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.

  2019cites this paper
• Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells.

  2018cites this paper
• The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines.

  2016cites this paper
• Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.

  2016cites this paper
• Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.

  2016cites this paper
• Mechanistic and Pharmacological Insights into Modulation of ABC Drug Transporters by Tyrosine Kinase Inhibitors

  2016cites this paper
• A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models

  2016cites this paper
• The Discovery of Dacomitinib, a Potent Irreversible EGFR Inhibitor

  2016cites this paper
• Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.

  2015cites this paper
• A tag-free collisionally induced fragmentation approach to detect drug-adducted proteins by mass spectrometry.

  2015cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations

  2014cites this paper
• Correction: Lapatinib-Binding Protein Kinases in the African Trypanosome: Identification of Cellular Targets for Kinase-Directed Chemical Scaffolds

  2014cites this paper
• New Chemical Scaffolds for Human African Trypanosomiasis Lead Discovery from a Screen of Tyrosine Kinase Inhibitor Drugs

  2014cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium

  2014cites this paper
• Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment

  2014cites this paper
• Clinical Trial Outcomes part of HER 2 / neu : an increasingly important therapeutic target . Part 3 : clinical applications and investigations

  2014cites this paper
• Screening therapeutic EMT blocking agents in a three-dimensional microenvironment.

  2013cites this paper
• Recent advances in drug design of epidermal growth factor receptor inhibitors.

  2013cites this paper
• Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.

  2013cites this paper
• Design and evaluation of radiolabeled tracers for tumor imaging

  2013cites this paper
• Lapatinib-Binding Protein Kinases in the African Trypanosome: Identification of Cellular Targets for Kinase-Directed Chemical Scaffolds

  2013cites this paper
• Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells

  2012cites this paper
• Role of epidermal growth factor receptor in breast cancer

  2012cites this paper
• What does a modified-Fibonacci dose-escalation actually correspond to?

  2012cites this paper
• ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective

  2012cites this paper
• HPLC-DAD protein kinase inhibitor analysis in human serum.

  2012cites this paper
• Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

  2011cites this paper
• Moving towards dose individualization of tyrosine kinase inhibitors.

  2011cites this paper
• The combination of pan-ErbB tyrosine kinase inhibitor CI-1033 and lovastatin: A potential novel therapeutic approach in squamous cell carcinoma of the head and neck

  2011cites this paper
• Emerging targeted therapies for breast cancer.

  2010cites this paper
• Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors

  2010cites this paper
• Targeted Therapies in Epithelial Ovarian Cancer

  2010cites this paper
• Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer

  2010cites this paper
• Receptor tyrosine kinase inhibitors as potent weapons in war against cancers.

  2009cites this paper
• Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.

  2009cites this paper
• [Antineoplastic oral agents and drug-nutrient interactions: a sistematic review].

  2009cites this paper
• Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.

  2009cites this paper
• Interacción de los antineoplásicos orales con los alimentos: revisión sistemática

  2009cites this paper
• Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer

  2009cites this paper
• Safety, pharmacokinetics and pharmacodynamics of targeted anti-cancer drugs

  2009cites this paper
• A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

  2009cites this paper
• Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.

  2008cites this paper
• Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.

  2008cites this paper
• Targeted therapies in breast cancer: established drugs and recent developments.

  2008cites this paper
• Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety

  2008cites this paper
• Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor

  2008cites this paper
• Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes

  2008cites this paper
• Targeted Therapies for Prostate Cancer

  2008cites this paper
• First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors

  2007cites this paper
• Rationale and Clinical Results of Multi-target Treatments in Oncology

  2007cites this paper
• Combination of radiotherapy with EGFR antagonists for head and neck carcinoma

  2007cites this paper
• Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.

  2007cites this paper
• Emerging therapies for colorectal cancer

  2007cites this paper
• Pharmacology of Epidermal Growth Factor Inhibitors

  2007cites this paper
• Molecular Targeted Therapies in the Treatment of Ovarian Cancer

  2007cites this paper
• Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

  2007cites this paper
• The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer

  2007cites this paper
• Rationale and clinical results of multi-target treatments in oncology.

  2007cites this paper
• Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.

  2007cites this paper
• Pharmacology of epidermal growth factor inhibitors.

  2007cites this paper
• A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors

  2006cites this paper
• A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer

  2006cites this paper
• Multitargeted therapy: can promiscuity be praised in an era of political correctness?

  2006cites this paper
• Inhibitors of signal transduction protein kinases as targets for cancer therapy.

  2006cites this paper
• Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.

  2006cites this paper
• Her-2 targeted therapy: Beyond breast cancer and trastuzumab

  2006cites this paper
• Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study

  2006cites this paper
• APhase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combinationwith Docetaxel in Patients with Advanced Solid Tumors

  2006cites this paper
• Current status and perspective of antiangiogenic therapy for cancer: urinary cancer

  2006cites this paper
• Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.

  2006cites this paper
• Integration of EGFR inhibitors with radiochemotherapy

  2006cites this paper
• Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf,and MEK

  2006cites this paper
• Novel therapies in colon cancer

  2006cites this paper
• Integration of EGFR inhibitors with radiochemotherapy

  2006cites this paper
• Cancer therapies targeted to the epidermal growth factor receptor and its family members

  2006cites this paper
• Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.

  2006cites this paper
• Targeted therapies in gynecologic cancers.

  2006cites this paper
• Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

  2005cites this paper
• Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.

  2005cites this paper
• Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer

  2005cites this paper
• The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck

  2005cites this paper
• EGFR inhibitors in lung cancer.

  2005cites this paper
• Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line

  2005cites this paper
• Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer

  2005cites this paper
• Role of Tyrosine Kinase Inhibitors in Cancer Therapy

  2005cites this paper
• Targeting the HER-kinase axis in cancer.

  2004cites this paper
• New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers.

  2004cites this paper
• Targeting ErbB receptor signaling: a pan-ErbB approach to cancer.

  2004cites this paper
• Epidermal growth factor receptor tyrosine kinase inhibitors

  2004cites this paper